AIDS drugs manufacturers drop case

Today 39 pharmaceutical companies unconditionally dropped their case against the South African government. A turning point in the case may have been persuasive evidence that the companies have no economic basis for the huge prices they charge for AIDS drugs.

Written byRobert Walgate
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

LONDON South Africa's Treatment Action Campaign and its friends are crowing with delight, as 39 pharmaceutical companies this morning withdrew their lawsuit to prevent South Africa from importing inexpensive generic copies of patented AIDS drugs. They will also pay defendants' costs. The manufacturers had argued their patent rights had been infringed by the South African government three years ago. The government had claimed the AIDS epidemic is an emergency under the TRIPS international patent agreements — and so it was free to import cheap generics. The manufacturers disagreed but now they have lost the war, and won only some appalling public relations for their attitude to Third World countries.

The South African Minister of Health has assured the Treatment Action Campaign (TAC) that no concessions have been made and that the government will now proceed to implement the 'Medicines and Related Substance Control Amendment Act', which led to the companies' ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo

Products

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

brandtechscientific-logo

BRANDTECH Scientific Launches New Website for VACUU·LAN® Lab Vacuum Systems